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Available online 25 May 2016Reprogrammable mouse models engineered to conditionally express Oct-4, Klf-4, Sox-2 and c-Myc (OKSM) have
been instrumental in dissectingmolecular events underpinning the generation of induced pluripotent stem cells.
However, until now these models have been reported in the context of the m2 reverse tetracycline-controlled
transactivator, which results in low reprogramming efﬁciency and consequently limits the number of
reprogramming intermediates that can be isolated for downstream proﬁling. Here, we describe an improved
OKSM mouse model in the context of the reverse tetracycline-controlled transactivator 3 with enhanced
reprogramming efﬁciency (N9-fold) and increased numbers of reprogramming intermediate cells albeit with
similar kinetics, which we believe will facilitate mechanistic studies of the reprogramming process.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ten years ago it was shown that mature cell types can be reverted
back towards a pluripotent state by the forced expression of Oct-4, Klf-
4, Sox-2 and c-Myc (OKSM) with tremendous implications for the regen-
erative medicine ﬁeld (Takahashi & Yamanaka, 2006; Stadtfeld &
Hochedlinger, 2010). However, only in recent yearswe have started un-
derstanding the molecular mechanisms that underpin the
reprogramming process into these so called induced pluripotent stem
cells (iPSC) (Woltjen et al., 2009; David & Polo, 2014; Alaei-Shehni et
al., 2014; Firas et al., 2015; Polo et al., 2012). The establishment of repro-
grammable mouse models, genetically engineered to conditionally ex-
press the four factors from a deﬁned locus, have been instrumental in
these efforts (Carey et al., 2009; Stadtfeld et al., 2010). Arguably the
most widely used reprogrammable mouse model is the m2rtTA-OKSM
mouse (Stadtfeld et al., 2010) which harbours (I) a multicistronic
OKSM cassette with an inducible promoter at the Collagen1a1 locus,
(II) them2 reverse tetracycline-controlled transactivator (m2rtTA) con-
stitutively expressed from the Rosa26 locus and (III) a GFP reporter
under control of the endogenousOct-4 promoter. Reprogramming is in-
duced in cells from these mice by exposure to doxycycline (dox)y and Developmental Biology,
ustralia.
. Nefzger),
. This is an open access article underreversibly activating OKSM expression (Stadtfeld et al., 2010). Com-
pared to traditional methods of iPSC generation using lenti- and retrovi-
ruses, them2rtTA-OKSMmouse model has proven advantageous as it is
more efﬁcient (increased reprogramming frequency) and allows tem-
poral control over transgene expression from a deﬁned locus
(Stadtfeld et al., 2010). Nevertheless, reprogramming is still a rare
event that the majority of cells are refractory to (Stadtfeld et al.,
2010). Accordingly, in order for the molecular mechanism of the
reprogramming process to be studied, only cell populations poised to
becoming iPSC have to be isolated and used for proﬁling. However,
due to the low reprogramming efﬁciency, the collection of intermedi-
ates is currently a very cost and labour intensive process (Polo et al.,
2012; Hansson et al., 2012).
Thus far, the molecular events of the reprogramming process have
been studied most extensively for mouse embryonic ﬁbroblasts
(MEFs). Successfully reprogramming MEFs from the m2rtTA-OKSM
mouse model initially loose identity cell surface marker THY1 followed
by reactivation of pluripotency associated cell surface marker SSEA1
(Polo et al., 2012; Stadtfeld et al., 2008). A subset of SSEA1 positive
cells is able to activate late stage reprogramming marker EPCAM,
followed by reactivation of the endogenous pluripotency network
(Oct4-GFP expression) (Polo et al., 2012; Stadtfeld et al., 2010). Cells re-
fractory to reprogramming on the other hand, distinguish themselves
from reprogramming intermediates by their inability to downregulate
THY1 expression and the fact that they contain less OKSM protein
(Polo et al., 2012). We have recently shown that these refractory
cells can be rescued by superfection with additional OKSM virus (Polothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rate-limiting. Consequently, we hypothesized that cells from a mouse
model with higher expression levels of OKSM at the cell population
level should reprogram more efﬁciently. To achieve this, we exchanged
the m2rtTA for the reverse tetracycline-controlled transactivator 3
(rtTA3), which has been shown to bemore efﬁcient in activating dox in-
ducible promoters (Das et al., 2004). The resulting rtTA3-OKSMmouse
model is characterized by higher protein levels of the reprogramming
factors and an over nine-fold increased reprogramming efﬁciency com-
pared to them2rtTA-OKSMmousemodel, while reprogramming kinetics
remained conserved between both models.
2. Materials and methods
2.1. Breeding
Embryos hetero/hemizygous for theOKSM, rtTA3 andOct4-GFP locus
were generated by crossing animals homozygous for the OKSM cassette
with animals both hemizygous for theCAG-rtTA3 locus andhomozygous
for the Oct4-GFP locus (Fig. 1a). Embryos heterozygous for the OKSM,
m2rtTA and Oct4-GFP locus were generated by crossing animals homo-
zygous for the OKSM cassette with animals homozygous for both the
m2rtTA and theOct4-GFP locus. Founder animalswith theOKSM cassetteFig. 1.Reprogrammingpotential: (a) Schematic of breeding strategy for the rtTA3-OKSMmouse
100 μm (c) qPCR to test expression levels of OKSM cassette and endogenous Oct4 transcri
reprogramming (+dox) and in established iPSC (−dox) (n = 3, biological replicates). (d) R
presence of derivatives of all three germ layers; Scale bar: 50 μm. (e) Western blot analysis
rtTA3-OKSM mouse model (*exogenous protein, **endogenous protein). (f) Alkaline phosp
biological replicates). (h) Point of no return experiment: Quantiﬁcation of number of AP posit
2, biological replicates).(https://www.jax.org/strain/011001), rtTA3 cassette (https://www.jax.
org/strain/016532),* m2rtTA cassette (https://www.jax.org/strain/
006965) and Oct4-GFP reporter (https://www.jax.org/strain/008214)
can be purchased from the Jackson Institute (Bar Harbor, USA). *Please
note that the CAG-rtTA3 cassette has to be maintained hemizygously
to not impact negatively on fertility.
2.2. Generation of mouse embryonic ﬁbroblasts
Mouse embryonic ﬁbroblast (MEFs) were generated from embryon-
ic day (E) 13.5 embryos as described previously (Nefzger et al., 2014).
2.3. Western blot
Nuclear extracts were prepared from approximately one million
cells as described previously (Andrews & Faller, 1991). Protein samples
were separated on 4–12% Bis-Tris gels (NuPAGE Cat. No. NP0335BOX,
Life Technologies) under reducing conditions with 14 μg nuclear ex-
tracts loaded per lane. They were then transferred onto nitrocellulose
membranes (NuPAGE; Invitrogen) followed by immunoblotting with
the primary antibodies (rabbit anti-OCT-4 Cat. No. ab19857, Abcam
and mouse anti-GAPDH Cat. No. MAB374, Millipore) and ﬂuorescently
labelled secondary antibodies (IRDye 800RD Donkey anti-rabbit Cat.model. (b)White light andﬂuorescent image of rtTA3-OKSM derived iPSC colony; Scale bar:
pts relative to housekeeping gene Gapdh for rtTA3-OKSM model in MEFs, on day 6 of
epresentative histology sections from an rtTA3-OSKM derived teratoma conﬁrming the
for GAPDH, OCT-4 and SOX-2 in MEFs, day 6 intermediates and iPSC of the m2rtTA and
hatase (AP) labelling on day 16 and (g) quantiﬁcation of AP positive colonies (n = 3,
ive colonies on day 16 with varying periods of dox exposure as indicated on x-axis (n =
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68072, LI-COR Biosciences). Following strippingwith Odyssey Stripping
buffer (Newblot Nitro Stripping buffer Cat. No. 928-40030, LI-COR Bio-
sciences), the membranes were re-probed (rabbit anti-SOX-2
ab59776, Abcam and IRDye 680RD Donkey anti-rabbit 926-68073, LI-
COR Biosciences).Membraneswere recordedwith the Odyssey Infrared
Imaging System (Li-Cor Biotechnology).
2.4. Cell culture
MEFs (passage 2)were reprogrammed in a 6-well format by seeding
2000 cells per cm2 in the presence of doxycycline (dox) for 12 days,
followed by 4 days of culture in the absence of dox as described in detail
previously (Nefzger et al., 2014).
2.5. Alkaline phosphatase assay
Cultures were washed with Phosphate Buffered Saline and stained
with an alkaline phosphatase kit (Vector Red Substrate Kit Cat. No. SK-
5100, Vector Laboratories) according to themanufacturer's instructions.
2.6. Teratoma formation assay
1 × 106 mouse iPSC were injected subcutaneously into the dorsal
ﬂanks of immuno-deﬁcient 5–8 week old female NOD-SCID mice.
After 4 weeks, teratomas were harvested and ﬁxed in 4% paraformalde-
hyde, embedded in parafﬁn, sectioned at 5 μm and stained with
haematoxylin and eosin.
2.7. Flow cytometry analysis
Cells were harvested, labelled and ﬂow cytometry performed as de-
scribed previously (Nefzger et al., 2014). THY1.2-PB (1:400 dilution of
anti-mouse CD90.2 eFluor 450 Cat. No. 48-0902-82, eBioscience),
SSEA1-biotin (1:400 dilution of anti-hu/mo SSEA-1 Biotin Cat. No. 13-
8813, eBioscience) and EPCAM-PE (1:200 dilution of PE rat anti-
mouse CD326 Cat. No. 563477, BD Biosciences) were used for the pri-
mary labelling step and Streptavidin PE-Cy7 (1:200 dilution of
Streptavidin PE-Cy7 Cat. No. 25-4317-82, eBioscience) was used for
the secondary labelling step.
2.8. Imaging
AMotic AE2000 lightmicroscope andMotic Images Plus2.0 software
were used to take bright ﬁeld images.
2.9. qPCR
RNA isolation, cDNA synthesis, qPCR and data analysis where per-
formed as described previously (Nefzger et al., 2016). The following
primer pairs were used for detection: OKSM-cassette (F:
AGTGCCAGAAGTGTGACAGG, R: CAAGAAGACAGGGCCAGGTT),
Oct4-endogenous (F: TAGGTGAGCCGTCTTTCCAC, R: GCTTAGCCA
GGTTCGAGGAT), Gapdh (F: CTCGTCTCATAGACAAGATGGTGAAG, R:
AGACTCCACGACATACTCAGCACC).
2.10. Genotyping
Embryo heads or tails were used for DNA isolation as described pre-
viously (Nefzger et al., 2014). Genotyping of the OKSM and the m2rtTA
locus were also performed as described previously (Nefzger et al.,
2014). For detection of the CAG-rtTA3 cassette the following
primer pairs (F: CGGTATCGAAGGCCTGACGACAAGG, R:
AGAAGCCTTGCTGACACAGGAACGC) and PCR conditions (94 °C for
3 min; 94 °C for 30 s, 65 °C for 40 s, 72 °C for 50 s × 35 cycles; 72 °C
for 5 min) were used. DNA from animals harbouring the CAG-rtTA3cassette produced a ~200 bp long fragment; wild type animals pro-
duced no band.
2.11. Statistical analysis
Experiments were performed as biological replicates. To assess sta-
tistical differences unpaired Student's t-test (2-tailed) was performed.
3. Results and discussion
To generate an OKSMmouse model with higher reprogramming ef-
ﬁciency we exchanged the m2rtTA for the more efﬁcient rtTA3 (Das et
al., 2004). We used founder animals which can be found commercially
available at the Jackson Institute and applied a breeding strategy to pro-
duce embryos hetero/hemizygous for the Oct4-GFP reporter, OKSM cas-
sette and rtTA3 by crossing mice homozygous for the OKSM cassette
with mice hemizygous for the rtTA3 locus and homozygous for the
Oct4-GFP locus (Fig. 1a). This strategy allowed us to produce approxi-
mately 50% of individuals in the F1 generation that were hemi/hetero-
zygous for all three loci; we called this the rtTA3-OSKM
reprogrammable mouse model (Fig. 1a). In order to verify that cells
from the rtTA3-OKSMmouse model are able to give rise to iPSC, we ex-
posed MEFs to doxycycline for 12 days as we did previously for MEFs
from them2rtTA-OKSMmodel (Polo et al., 2012). Indeed, iPSC colonies
emerged during this period which could be propagated under doxycy-
cline-free conditions and had activated the Oct4-GFP reporter as visual-
ized by ﬂuorescence microscopy (Fig. 1b). We conﬁrmed by
quantitative PCR that these iPSC expressed endogenous Oct-4 tran-
scripts but no longer the inducible OKSM cassette (Fig. 1c) suggesting
they had reactivated the endogenous pluripotency network (Stadtfeld
et al., 2010). In order to establish the pluripotent differentiation poten-
tial of these newly derived rtTA3-OKSM derived iPSC,we examined their
ability to give rise to derivatives of all three germ layers in teratoma as-
says (Fig. 1d). In support of this, subcutaneous injection of rtTA3-iPSC
into the dorsalﬂanks of immunocompromisedNODSCIDmice produced
teratomas with ectodermal, mesodermal and endodermal tissues
(Fig. 1d). Altogether, these experiments demonstrate that the cells we
obtained from the rtTA3-OKSM mouse model were able to reprogram
to bona ﬁde iPSC.
We next examined whether reprogramming intermediates of the
rtTA3-OKSM mouse model have an increased amount of the
reprogramming factors compared to intermediates of the m2-OKSM
model. Western blot analysis of SSEA1 positive m2rtTA and rtTA3
reprogramming intermediates (both at day 6) demonstrated that
rtTA3-OKSM intermediates contained higher levels of transgene proteins
OCT-4 and SOX-2 compared to cells derived from the m2rtTA-OKSM
model (Fig. 1e). As hypothesized, this increase in reprogramming fac-
tors at the population level in rtTA3 relative to m2rtTA reprogramming
intermediates was reﬂected by a signiﬁcantly higher (Nnine-fold)
reprogramming efﬁciency as demonstrated by quantiﬁcation of alkaline
phosphatase positive colonies after MEFs were exposed to dox for
12 days followed by 4 days of dox withdrawal (Fig. 1f, g). In order to in-
terrogate whether this enhancement in reprogramming efﬁciency af-
fected the reprogramming kinetics, we ﬁrst determined the number of
days that the cells required the transgenes to be active. As shown in
Fig. 1h, MEFs of both models required a minimum of nine days of dox
exposure to generate iPSC colonies. Next, we determined whether the
sequence and timing of surface marker expression were the same for
both models. To do this, MEFs of both models (m2rtTA and rtTA3)
were reprogrammed (12 days of dox exposure followed by repeated
passaging as iPSC under dox free conditions) and ﬂow cytometry anal-
ysis was performed on days 0, 3, 6, 9 aswell as at the iPSC state to deter-
mine expression levels of THY1, SSEA1, EPCAM and Oct4-GFP. As
previously published for the m2rtTA-OKSM model (Polo et al., 2012),
we observed that also rtTA3 reprogramming intermediates from MEFs
progress from a THY1+ to a THY1− to a SSEA1+ state in the ﬁrst six
Fig. 2.Reprogramming kinetics: (a)White light images and representative FACS blots for reprogramming rtTA3-OKSM cultures on days 0, 3, 6, 9 and at the iPSC state; Scale bar: 500 μm(b)
Representative pie charts depicting culture composition (m2rtTA-OKSM versus rtTA3-OKSM) at various time points.
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and 12 (Fig. 2a, b). This change in surface marker expression is concur-
rent withmorphological changes and eventual colony formation by day
9 (Fig. 2a). At each time point analyzed, we observed that
reprogramming cultures of the rtTA3-OKSMmouse model contained a
4–9-fold higher percentage of reprogramming intermediates than
m2rtTA cultures (Fig. 2b) in agreement with the observed enhanced
reprogramming efﬁciency. In order to facilitate the planning of experi-
ments where intermediate cell populations are to be isolated forTable 1
Expected number of intermediate cells for reprogramming rtTA3-OKSMMEFs.
MEFs per cm2 Cells per cm2 collection day
Day 3 2 ∗ 103 ~4 ∗ 104
Day 6 2 ∗ 103 ~2.5 ∗ 105
Day 9 1 ∗ 103 ~3 ∗ 105
Day 12 1 ∗ 103 ~3 ∗ 105downstream applications, the expected number of reprogramming in-
termediates that can be harvested on days 3, 6, 9 and 12 per cm2 of
MEFs seeded on day 0 is illustrated in Table 1.
4. Conclusion
Cellular reprogramming is an inefﬁcient process and obtaining the
rare reprogramming intermediates is a major hurdle in understanding
this important event at the molecular level. The application of certainReprogramming intermediates per cm2 Cell surface marker proﬁle
~4 ∗ 103 SSEA1+ EPCAM-
~6 ∗ 104 SSEA1+ EPCAM-
~3 ∗ 104 SSEA1+ EPCAM+
~3 ∗ 104 SSEA1+ EPCAM+
53S. Alaei et al. / Stem Cell Research 17 (2016) 49–53techniques that require higher cell numbers such as transcription factor
chromatin immunoprecipitation (ChIP), DNase-sequencing or mass
spectrometry approaches is therefore time and cost intensive. Here,
we present an improved OKSM reprogrammable mousemodel facilitat-
ed by the use of the rtTA3 which is characterized by a more than nine-
fold higher reprogramming efﬁciency and signiﬁcantly increased yields
of the rare reprogramming intermediates without affecting
reprogramming kinetics or the sequence of cell surfacemarker changes.
Hence, we believe that the rtTA3-OKSM mouse model will become a
useful tool for the isolation of the rare reprogramming intermediates
at signiﬁcantly higher yields and will consequently facilitate the study
of the reprogramming process by enabling techniques that require a
large number of cells.
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